Point72 Asset Management’s Pacific Biosciences PACB Stock Holding History

Point72 Asset Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$377K	Sell	285,700 -2,671,700	-90%	-$4.78M	﹤0.01%	3262
2025 Q4	$5.53M	Buy	+2,957,400	New	+$5.68M	0.01%	1772
2025 Q3	–	Sell	-914,190	Closed	-$1.13M	–	2591
2025 Q2	$1.13M	Buy	+914,190	New	+$1.06M	﹤0.01%	1511
2024 Q1	–	Sell	-5,349,146	Closed	-$31.3M	–	2511
2023 Q4	$52.5M	Buy	5,349,146 +2,755,364	+106%	+$22.5M	0.13%	204
2023 Q3	$21.7M	Sell	2,593,782 -4,067,851	-61%	-$46.5M	0.06%	390
2023 Q2	$88.6M	Sell	6,661,633 -627,735	-9%	-$7.63M	0.26%	91
2023 Q1	$84.4M	Buy	7,289,368 +1,957,373	+37%	+$19.5M	0.26%	90
2022 Q4	$43.6M	Buy	5,331,995 +2,797,889	+110%	+$24.1M	0.15%	184
2022 Q3	$14.7M	Buy	+2,534,106	New	+$14.5M	0.06%	403
2021 Q1	–	Sell	-40,000	Closed	-$1.04M	–	1123
2020 Q4	$1.04M	Sell	40,000 -2,271,631	-98%	-$38.6M	0.01%	804
2020 Q3	$22.8M	Buy	+2,311,631	New	+$13.3M	0.12%	242
2018 Q4	–	Sell	-5,175,000	Closed	-$28M	–	1150
2018 Q3	$28M	Buy	5,175,000 +2,275,000	+78%	+$9.76M	0.12%	227
2018 Q2	$10.3M	Buy	2,900,000 +800,000	+38%	+$2.22M	0.04%	437
2018 Q1	$4.3M	Buy	+2,100,000	New	+$5.45M	0.02%	609
2017 Q2	–	Sell	-1,279,200	Closed	-$6.61M	–	958
2017 Q1	$6.61M	Buy	+1,279,200	New	+$6.26M	0.04%	477
2016 Q2	–	Sell	-706,500	Closed	-$6M	–	837
2016 Q1	$6M	Buy	706,500 +700,300	+11,295%	+$6.89M	0.05%	401
2015 Q4	$81K	Sell	6,200 -10,900	-64%	-$97.8K	﹤0.01%	655
2015 Q3	$63K	Buy	17,100 +17,000	+17,000%	+$83.1K	﹤0.01%	716
2015 Q2	$1K	Buy	+100	New	+$579	﹤0.01%	702

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management's PACB Position: Q1 2026 in Review

Point72 Asset Management reduced its Pacific Biosciences (PACB) stake by 90% in Q1 2026, selling an estimated $4.78M and leaving 285,700 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #3262.

Point72 Asset Management first reported a position in PACB in Q2 2015 and has held it in 19 quarters since. The position peaked at $88.6M in Q2 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Point72 Asset Management held 285,700 shares of Pacific Biosciences worth $377K as of Q1 2026.
Point72 Asset Management sold 2,671,700 Pacific Biosciences shares in Q1 2026, an estimated $4.78M.
Pacific Biosciences made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3262 holding.
Point72 Asset Management first reported a position in Pacific Biosciences in Q2 2015 and has held it in 19 quarters since.
Point72 Asset Management's Pacific Biosciences position peaked at $88.6M in Q2 2023.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.